151 related articles for article (PubMed ID: 7823594)
1. Tumor suppressor genes in prostatic oncogenesis.
Bookstein R
J Cell Biochem Suppl; 1994; 19():217-23. PubMed ID: 7823594
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
3. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
4. Alterations of tumor suppressor genes in bladder cancer.
Cordon-Cardo C; Reuter VE
Semin Diagn Pathol; 1997 May; 14(2):123-32. PubMed ID: 9179973
[TBL] [Abstract][Full Text] [Related]
5. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer.
Massenkeil G; Oberhuber H; Hailemariam S; Sulser T; Diener PA; Bannwart F; Schäfer R; Schwarte-Waldhoff I
Anticancer Res; 1994; 14(6B):2785-90. PubMed ID: 7872719
[TBL] [Abstract][Full Text] [Related]
6. p53 is mutated in a subset of advanced-stage prostate cancers.
Bookstein R; MacGrogan D; Hilsenbeck SG; Sharkey F; Allred DC
Cancer Res; 1993 Jul; 53(14):3369-73. PubMed ID: 8324747
[TBL] [Abstract][Full Text] [Related]
7. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
8. An uncertain role for p53 gene alterations in human prostate cancers.
Brooks JD; Bova GS; Ewing CM; Piantadosi S; Carter BS; Robinson JC; Epstein JI; Isaacs WB
Cancer Res; 1996 Aug; 56(16):3814-22. PubMed ID: 8706029
[TBL] [Abstract][Full Text] [Related]
9. The MXI1 tumor suppressor gene is not mutated in primary prostate cancer.
Kuczyk MA; Serth J; Bokemeyer C; Schwede J; Herrmann R; Machtens S; Grünewald V; Höfner K; Jonas U
Oncol Rep; 1998; 5(1):213-6. PubMed ID: 9458379
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss.
Dong JT; Suzuki H; Pin SS; Bova GS; Schalken JA; Isaacs WB; Barrett JC; Isaacs JT
Cancer Res; 1996 Oct; 56(19):4387-90. PubMed ID: 8813131
[TBL] [Abstract][Full Text] [Related]
11. [p53 in urogenital tumors:analysis of expression and mutation].
Löning T; Schlechte H; Friedrichs K; Schnoor D; Ditscherlein G; Bommer G; Löning S
Verh Dtsch Ges Pathol; 1993; 77():117-8. PubMed ID: 7511267
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology of prostate cancer.
Isaacs WB; Bova GS; Morton RA; Bussemakers MJ; Brooks JD; Ewing CM
Semin Oncol; 1994 Oct; 21(5):514-21. PubMed ID: 7939745
[TBL] [Abstract][Full Text] [Related]
13. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas.
Huang Y; Meltzer SJ; Yin J; Tong Y; Chang EH; Srivastava S; McDaniel T; Boynton RF; Zou ZQ
Cancer Res; 1993 Apr; 53(8):1889-94. PubMed ID: 8467510
[TBL] [Abstract][Full Text] [Related]
14. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
15. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE).
Schlechte HH; Schnorr D; Löning T; Rudolph BD; Pohrt UM; Loening SA
J Urol; 1997 Mar; 157(3):1049-53. PubMed ID: 9072541
[TBL] [Abstract][Full Text] [Related]
16. Alterations of p53 are common in early stage prostate cancer.
Downing SR; Russell PJ; Jackson P
Can J Urol; 2003 Aug; 10(4):1924-33. PubMed ID: 14503938
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer.
Jenkins R; Takahashi S; DeLacey K; Bergstralh E; Lieber M
Genes Chromosomes Cancer; 1998 Feb; 21(2):131-43. PubMed ID: 9491325
[TBL] [Abstract][Full Text] [Related]
18. Alterations of the retinoblastoma gene in human prostate adenocarcinoma.
Tricoli JV; Gumerlock PH; Yao JL; Chi SG; D'Souza SA; Nestok BR; deVere White RW
Genes Chromosomes Cancer; 1996 Feb; 15(2):108-14. PubMed ID: 8834174
[TBL] [Abstract][Full Text] [Related]
19. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
20. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q.
Yin Z; Babaian RJ; Troncoso P; Strom SS; Spitz MR; Caudell JJ; Stein JD; Kagan J
Oncogene; 2001 Apr; 20(18):2273-80. PubMed ID: 11402322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
